ALTSTATION.IO

Kenvue Inc. (KVUE) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$18.14

Change

+0.37%

Market Cap

$34.75B

Avg Volume

42.1M

Company Overview

Kenvue Inc. is a consumer health company based in Summit, New Jersey. They sell a wide range of personal care and household products across several segments, including Self Care, Skin Health and Beauty, and Essential Health. Their product lineup includes well-known brands such as Tylenol, Neutrogena, Listerine, and Johnson’s. Customers range from everyday consumers seeking health and wellness solutions to families in need of personal care items.

Kenvue occupies a strong position in the consumer defensive sector, operating as a market leader with a diverse product portfolio. They face competition from major players like Procter & Gamble and Unilever, but their established brands give them an edge in consumer trust and loyalty. However, increasing competition from emerging brands and private labels presents a constant threat to their market share, particularly in a cost-sensitive environment.

Currently, Kenvue is in a growth phase. Since its incorporation in 2022, the company has been focused on strategic expansion and optimizing its product offerings. Recent milestones include enhancing their supply chain efficiency and driving innovation in their product lines, which positions them well to capitalize on consumer trends toward health consciousness and premium personal care products.

Key Financials

Market Cap

$34.75B

Revenue

$15.01B

EBITDA

$3.54B

Gross Margin

58.3%

Profit Margin

9.6%

Revenue Growth

-3.5%

Total Cash

$1.14B

Total Debt

$9.11B

Free Cash Flow

$1.75B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

24.18

Forward P/E

16.45

Beta

0.55

52-Week High

$25.17

52-Week Low

$14.02

EPS

$0.75

50-Day Avg

$17.22

200-Day Avg

$19.31

Price/Book

3.27

Technical Analysis

Kenvue Inc. (KVUE) has displayed a declining overall trend over the past 52 weeks, with a notable drop from a high of approximately $24 in February to a current price of $18.14, reflecting an 8.3% decline. Key resistance is evident at the $20 level, where the stock struggled to maintain upward momentum throughout the year, while strong support is forming near $18.13, particularly in recent weeks. Price patterns show a series of lower highs and lower lows, indicative of a bearish structure, although there has been recent consolidation around the $18-$18.14 range. Over the past few weeks, the stock has exhibited slight upward momentum, suggesting potential reversal attempts as it pushes against its established support level. Currently, at $18.14, KVUE is trading just above its key support and near the lower end of its 52-week range, which implies caution for investors, as sustained failures to break above the resistance could lead to further downside.

Recent News and Developments

Here’s a summary of the latest news and developments for Kenvue Inc

(KVUE) stock from the past week:

1. Kenvue Shareholders Approve Kimberly-Clark Acquisition

Kenvue Inc. shareholders overwhelmingly approved the acquisition by Kimberly-Clark Corporation on January 29, 2026. Approximately 99% of shares voted at Kenvue’s Special Meeting were in favor of adopting the merger agreement, representing about 77% of all outstanding shares. The transaction is anticipated to close in the second half of 2026, pending regulatory approvals and other customary closing conditions.

2. Kenvue to Announce Q4 and Full-Year 2025 Results on February 17, 2026

Kenvue Inc. is scheduled to release its financial results for the fourth quarter and full year 2025 after the market closes on February 17, 2026. Due to the pending acquisition by Kimberly-Clark, the company will not be holding a quarterly conference call to discuss its results.

Market Sentiment and Analyst Recommendations

Bull Case

The Kimberly-Clark acquisition at ~$18 per share creates a floor for downside risk. With 99% shareholder approval and expected close in H2 2026, execution risk is minimal. The stock trades right at support ($18.13) after a 28% decline from its 52-week high, leaving room for mean reversion if sentiment shifts. Director Jeffrey Smith’s 13.27% stake increase at $17.37 signals insider confidence. At 24.18x P/E on $15.01B revenue, KVUE isn’t expensive for a consumer staples company with established brands. The $1.14B cash position provides flexibility for shareholder returns or strategic investments post-merger.

Bear Case

Revenue declined 3.5% year-over-year, which is the real problem here. A consumer health company losing top-line momentum suggests competitive pressure or market share loss that the merger doesn’t fix. The $9.11B debt load is substantial relative to the $1.14B cash position, limiting financial flexibility. Analysts have been cutting EPS estimates (down 2.14% in 60 days) and downgrading from Buy to Hold, with Jefferies specifically noting limited upside given the deal price. The stock is trapped between $18 and $20 resistance, unable to break out despite insider buying. Until the acquisition closes, KVUE is a merger arbitrage play, not a growth story, with minimal catalyst for appreciation above $18.92.

What to Watch

Q4 2025 earnings on February 17 will reveal whether the revenue decline accelerated or stabilized. Watch for gross margin pressure and commentary on brand performance in key categories. The merger timeline is critical–any regulatory delays or deal uncertainty would crater the stock below $18 support. Track whether KVUE can hold above $18.13 or breaks lower; a sustained break below $17.50 signals capitulation. Monitor insider buying patterns; if Smith and other directors stop accumulating, conviction weakens. The $20 resistance level needs to break convincingly for any bullish reversal. Finally, watch Kimberly-Clark’s own earnings and deal commentary for any signals about integration plans or post-merger strategy changes.

Analyst Consensus

HOLD

Based on 12 analyst opinions

Low Target

$17.00

Mean Target

$18.92

High Target

$23.00

Earnings and Financial Data

Sector

Consumer Defensive

Industry

Household & Personal Products

Employees

22,000

Earnings & Dividends

Next Earnings

Feb 17, 2026

EPS (Trailing)

$0.75

Dividend Yield

459.0%

Payout Ratio

109.7%

Frequently Asked Questions

Is KVUE a good stock to buy?

Currently, KVUE has a hold recommendation with a target price of $18.92, slightly above its current price of $18.14. Given the stagnant price movements and the forward P/E of 16.45, it’s better to wait for a stronger buying signal.

What is KVUE’s price target?

Analysts have set a price target of $18.92 for KVUE. This implies a potential upside of about 4.3% from its current price.

Does KVUE pay a dividend?

Yes, KVUE has an exceptionally high dividend yield of 459.0%. However, this figure may be misleading, as it warrants scrutiny regarding the sustainability of such dividends.

What is KVUE’s market cap?

KVUE has a market cap of $34.75 billion. This positions it firmly within the large-cap space, making it a more stable, but less aggressive, investment.

What is KVUE’s 52-week trading range?

KVUE has traded between $14.02 and $25.17 over the past year. This range highlights significant volatility, suggesting potential for future price movements, but also increases risk.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.